In conclusion, in our study, we developed a prognostic risk model with 7 differentially expressed AGs, which has great potential as an immunosuppressive and inflammatory state biomarker in HNSCC patients and provides insight into individualized immunotherapy for HNSCC patients. This evidence concerns the gene JAG1 and head and neck squamous cell carcinoma.